HK1257781A1 - 含抗-pd-1抗體avelumab的水性藥物製劑 - Google Patents

含抗-pd-1抗體avelumab的水性藥物製劑

Info

Publication number
HK1257781A1
HK1257781A1 HK19100169.4A HK19100169A HK1257781A1 HK 1257781 A1 HK1257781 A1 HK 1257781A1 HK 19100169 A HK19100169 A HK 19100169A HK 1257781 A1 HK1257781 A1 HK 1257781A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulation
aqueous pharmaceutical
antibody avelumab
avelumab
antibody
Prior art date
Application number
HK19100169.4A
Other languages
English (en)
Inventor
G‧里納爾迪
A‧德爾里奧
S‧弗拉塔爾坎杰利
S‧福斯
M‧魏甘德特
Original Assignee
默克專利股份有限公司
輝瑞公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54838201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1257781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 默克專利股份有限公司, 輝瑞公司 filed Critical 默克專利股份有限公司
Publication of HK1257781A1 publication Critical patent/HK1257781A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK19100169.4A 2015-12-07 2019-01-04 含抗-pd-1抗體avelumab的水性藥物製劑 HK1257781A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15198233 2015-12-07
PCT/EP2016/002040 WO2017097407A1 (en) 2015-12-07 2016-12-05 Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab

Publications (1)

Publication Number Publication Date
HK1257781A1 true HK1257781A1 (zh) 2019-10-25

Family

ID=54838201

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100169.4A HK1257781A1 (zh) 2015-12-07 2019-01-04 含抗-pd-1抗體avelumab的水性藥物製劑

Country Status (35)

Country Link
US (2) US11058769B2 (zh)
EP (2) EP3386541B1 (zh)
JP (1) JP6925337B2 (zh)
KR (1) KR102697026B1 (zh)
CN (1) CN108367072B (zh)
AR (1) AR107014A1 (zh)
AU (1) AU2016368099C1 (zh)
BR (1) BR112018010211A2 (zh)
CA (1) CA3007481C (zh)
CL (1) CL2018001488A1 (zh)
CO (1) CO2018005525A2 (zh)
CY (1) CY1123358T1 (zh)
DK (1) DK3386541T3 (zh)
EA (1) EA201891339A1 (zh)
ES (1) ES2823279T3 (zh)
HK (1) HK1257781A1 (zh)
HR (1) HRP20201573T1 (zh)
HU (1) HUE050811T2 (zh)
IL (1) IL259563B (zh)
LT (1) LT3386541T (zh)
MX (1) MX2018006875A (zh)
MY (1) MY195681A (zh)
NZ (1) NZ743964A (zh)
PE (1) PE20181400A1 (zh)
PH (1) PH12018500894A1 (zh)
PL (1) PL3386541T3 (zh)
PT (1) PT3386541T (zh)
RS (1) RS61029B1 (zh)
SA (1) SA518391743B1 (zh)
SG (1) SG11201804758QA (zh)
SI (1) SI3386541T1 (zh)
TW (1) TWI630917B (zh)
UA (1) UA123270C2 (zh)
WO (1) WO2017097407A1 (zh)
ZA (1) ZA201804534B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MY194225A (en) 2015-03-13 2022-11-22 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
RS61029B1 (sr) 2015-12-07 2020-12-31 Merck Patent Gmbh Vodena formulacija koja sadrži avelumab antitelo na pd-1
PH12018502623A1 (en) 2016-06-13 2019-10-07 I Mab Anti-pd-l1 antibodies and uses thereof
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
SG11201908091QA (en) * 2017-03-06 2019-10-30 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
NZ759442A (en) 2017-06-01 2024-07-05 Cytomx Therapeutics Inc Activatable anti-pdl1 antibodies, and methods of use thereof
CN114632150B (zh) * 2017-11-02 2023-12-19 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
AU2018388301B2 (en) * 2017-12-22 2022-02-17 Samsung Bioepis Co., Ltd. Liquid composition comprising VEGF antagonist
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
WO2020108497A1 (zh) * 2018-11-29 2020-06-04 和铂医药（香港）有限公司 一种抗pd-l1抗体制剂
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
BR112021026414A2 (pt) * 2019-06-25 2022-04-12 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
TWI844666B (zh) * 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
WO2021091964A1 (en) 2019-11-04 2021-05-14 Duke University Treatment for primary and metastatic cancer
JP2023506629A (ja) * 2019-12-13 2023-02-17 サムスン バイオエピス カンパニー リミテッド 安定した抗ｐｄ－１抗体の薬剤学的製剤
KR102683876B1 (ko) * 2020-11-11 2024-07-11 가톨릭대학교 산학협력단 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트
IL309662A (en) 2021-07-02 2024-02-01 Univ Yale Compositions and methods for treating cancer
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5209476B2 (ja) 2005-09-02 2013-06-12 グリコミメティクス， インコーポレイテッド ヘテロ二官能性全セレクチン阻害剤
WO2007076354A2 (en) 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
CN108997498A (zh) * 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CA2783715A1 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
MX341076B (es) * 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
SI2785375T1 (sl) * 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
WO2013112438A1 (en) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EA201991715A1 (ru) 2013-09-27 2020-03-31 Дженентек, Инк. Композиции, содержащие антитело к pdl1
EP3057616B1 (en) * 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
KR20230144099A (ko) * 2014-05-15 2023-10-13 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
AU2016222928B2 (en) 2015-02-26 2021-05-13 Merck Patent Gmbh PD-1 / PD-L1 inhibitors for the treatment of cancer
TW201705955A (zh) 2015-05-14 2017-02-16 輝瑞大藥廠 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent Gmbh Pd-l1 antagonist combination treatments
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
RS61029B1 (sr) 2015-12-07 2020-12-31 Merck Patent Gmbh Vodena formulacija koja sadrži avelumab antitelo na pd-1
SG11201908091QA (en) 2017-03-06 2019-10-30 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation

Also Published As

Publication number Publication date
BR112018010211A2 (pt) 2019-02-05
TW201725051A (zh) 2017-07-16
DK3386541T3 (da) 2020-09-28
CA3007481A1 (en) 2017-06-15
AU2016368099A1 (en) 2018-07-19
AR107014A1 (es) 2018-03-14
NZ743964A (en) 2023-03-31
EA201891339A1 (ru) 2019-01-31
WO2017097407A1 (en) 2017-06-15
US20180369377A1 (en) 2018-12-27
PT3386541T (pt) 2020-10-12
ZA201804534B (en) 2020-11-25
CA3007481C (en) 2024-01-30
MY195681A (en) 2023-02-03
CN108367072B (zh) 2022-12-27
HUE050811T2 (hu) 2021-01-28
PH12018500894A1 (en) 2018-11-05
KR102697026B1 (ko) 2024-08-20
LT3386541T (lt) 2020-10-26
JP6925337B2 (ja) 2021-08-25
MX2018006875A (es) 2018-11-09
IL259563A (en) 2018-07-31
EP3747466A1 (en) 2020-12-09
SG11201804758QA (en) 2018-07-30
CO2018005525A2 (es) 2018-08-10
SA518391743B1 (ar) 2022-12-01
CL2018001488A1 (es) 2018-09-14
CY1123358T1 (el) 2021-12-31
PL3386541T3 (pl) 2021-04-06
AU2016368099C1 (en) 2023-10-12
IL259563B (en) 2021-05-31
HRP20201573T1 (hr) 2020-12-11
UA123270C2 (uk) 2021-03-10
JP2018536676A (ja) 2018-12-13
EP3386541A1 (en) 2018-10-17
ES2823279T3 (es) 2021-05-06
AU2016368099B2 (en) 2023-03-09
PE20181400A1 (es) 2018-09-07
US20210100903A1 (en) 2021-04-08
SI3386541T1 (sl) 2020-11-30
US11058769B2 (en) 2021-07-13
RS61029B1 (sr) 2020-12-31
TWI630917B (zh) 2018-08-01
KR20180085801A (ko) 2018-07-27
EP3386541B1 (en) 2020-07-08
CN108367072A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
HK1257781A1 (zh) 含抗-pd-1抗體avelumab的水性藥物製劑
HRP20182006T1 (hr) Farmaceutski pripravak anti-tnf-alfa antitijela
HUE055884T2 (hu) Gyógyszerkészítmény
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL268943A (en) Aqueous formulation of ANTI-PD-L1 antibody
HK1245653A1 (zh) 藥物製劑
IL253177A0 (en) Pharmacy preparation
IL266537A (en) pharmaceutical preparation
EP3383371C0 (en) PHARMACEUTICAL FORMULATION
ZA201807851B (en) Pharmaceutical formulation
HUE054716T2 (hu) Anti-EGFR-t tartalmazó gyógyászati készítmény
GB201506755D0 (en) Novel pharmaceutical formulation
GB201511246D0 (en) Pharmaceutical formulation
GB201719873D0 (en) Pharmaceutical formulation